Screener
Immix Biopharma, Inc. IMMX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Operating expenses: | ||
| General and administrative expenses | $4,823,378 | $2,707,851 |
| Research and development | 5,980,477 | 1,975,074 |
| Total operating expenses | 10,803,855 | 4,682,925 |
| Loss from operations | (10,803,855) | (4,682,925) |
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
Document
FAQ
- What is Immix Biopharma, Inc.'s total operating expenses?
- Immix Biopharma, Inc. (IMMX) reported total operating expenses of $10.8M in Q1 2026.
- How has Immix Biopharma, Inc.'s total operating expenses changed year-over-year?
- Immix Biopharma, Inc.'s total operating expenses increased by 130.7% year-over-year, from $4.68M to $10.8M.
- What is the long-term trend for Immix Biopharma, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s total operating expenses has grown at a 117.0% compound annual growth rate (CAGR), from $1.35M to $29.96M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Immix Biopharma, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude